Pancreatic carcinoma metastatic

5 trials 1 recruiting MedDRA PT
5 Registered trials
1 Recruiting
5 Unique sponsors
7 Unique IMPs
4 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 3
N Neurology/Psychiatry (ATC N) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Antimetabolite 1 substance
Taxane 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Topoisomerase I inhibitor 1 substance
Phase II/III: 1 Phase II: 2 Phase I/II: 1 Phase I (First in Human): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase II/III

1 trial
  • 1globe Health Institute LLC Commercial
    GEMCITABINE; NAPABUCASIN; PACLITAXEL
    2024-518205-17-00 2 countries 2022 n=84
    Ended

Phase II

2 trials
  • Seagen Inc. Commercial
    PEMBROLIZUMAB; TISOTUMAB VEDOTIN
    2023-503812-34-00 4 countries 2019 n=79
    Ended
  • University Of Cologne Academic
    IRINOTECAN
    2024-512951-18-00 1 country 2021 n=150 Orphan
    Halted

Phase I/II

1 trial
  • Merck Healthcare KGaA Commercial
    PRECEMTABART TOCENTECAN
    2024-517819-74-00 5 countries 2025 n=21
    Recruiting

Phase I (First in Human)

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502367-37-00 3 countries 2024 n=55
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
1globe Health Institute LLC Commercial 1 Phase II/III 0
Seagen Inc. Commercial 1 Phase II 0
Novartis Pharma AG Commercial 1 Phase I (First in Human) 0
Merck Healthcare KGaA Commercial 1 Phase I/II 1
University Of Cologne Academic 1 Phase II 0
New trials by year
2019
1
2021
1
2022
1
2024
1
2025
1
← All indication landscapes